Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation

Area of Science:

• Oncology
• Cancer Metabolism
• Melanoma Research

Background:

• Cancer cells exhibit altered metabolism, often relying on glycolysis (Warburg effect) over oxidative phosphorylation (OXPHOS).
• BRAF(V600E) mutations are key regulators in melanoma, influencing metabolic homeostasis and proliferation.
• Melanoma cells may shift metabolism to bypass senescence induced by BRAF(V600E), reducing OXPHOS dependence.

Purpose of the Study:

• To investigate the role of BRAF(V600E) in metabolic reprogramming in melanoma.
• To understand how BRAF(V600E) mutations affect mitochondrial oxidative phosphorylation (OXPHOS) and related factors.
• To explore the therapeutic potential of targeting BRAF-mediated metabolic adaptations.

Main Methods:

• Analysis of metabolic pathways in melanoma cells with BRAF(V600E) mutations.
• Investigating the impact of BRAF(V600E) on microphthalmia-associated transcription factor (MITF) and PGC1α expression.
• Evaluating the effects of BRAF(V600E) inhibition on cellular metabolism and OXPHOS levels.

Main Results:

• BRAF(V600E) suppresses MITF and PGC1α, contributing to reduced OXPHOS in melanoma.
• Therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming.
• BRAF(V600E) targeted therapy increases OXPHOS via elevated MITF-PGC1α levels.

Conclusions:

• BRAF(V600E) mutations drive metabolic adaptation in melanoma, promoting proliferation by limiting OXPHOS.
• BRAF-targeted therapies can restore OXPHOS, highlighting metabolic modulation as a therapeutic strategy.
• Combination therapies targeting adaptive metabolic responses may enhance efficacy against malignant melanoma.